Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02769832 · ClinicalTrials.gov registry record · Phase 2
Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer
A Phase 2 study, sponsored by Muhammad Furqan.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT02769832 is a Phase 2 study that has completed, run by Muhammad Furqan. The registered enrollment target is 32 participants.
The verdict
NCT02769832, a Phase 2 study, has completed, sponsored by Muhammad Furqan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this research study is to see if Abraxane and Gemcitabine given together will be effective in treating small cell cancer that has progressed after one line of treatment.
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-08-29 |
| Est. Completion | 2022-07-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02769832
The ClinicalTrials.gov registry entry for NCT02769832 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Muhammad Furqan, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT02769832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02769832 about?
NCT02769832 is a clinical study titled "Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer". The purpose of this research study is to see if Abraxane and Gemcitabine given together will be effective in treating small cell cancer that has progressed after one line of treatment.
What is the current status of trial NCT02769832?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2016-08-29. Estimated completion is 2022-07-07.
What interventions are being tested in trial NCT02769832?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02769832?
This trial is sponsored by Muhammad Furqan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.